西洛他唑联合尼可地尔对LEAOD患者baPWV、ABI指数及CD36水平的影响

Effect of cilostazol combined with nicorandil on baPWV,ABI and CD36 in patients with LEAOD

目的:探讨西洛他唑联合尼可地尔对下肢动脉硬化闭塞症(LEAOD)患者臂踝脉搏波传导速度(baPWV)、踝肱指数(ABI)及清道夫受体CD36水平的影响。方法:选取116例LEAOD患者作为研究对象,采用随机数字表法分为对照组和治疗组,每组58例。对照组患者采用西洛他唑治疗,治疗组在西洛他唑治疗的基础上联合尼可地尔治疗,比较两组临床治疗效果,治疗前后baPWV、ABI和CD36水平以及不良反应发生情况。结果:治疗结束后,有效率对照组仅为74.1%,而治疗组为91.4%,两组差异有统计学意义(P <0.05)。治疗前两组baPWV、ABI以及CD36水平均无显著性差异,治疗后两组均baPWV、CD36水平显著降低,ABI显著升高,但与对照组相比,治疗组baPWV和CD36水平降低更为明显,ABI升高更为显著(均P <0.05)。对照组和治疗组不良反应发生率分别为15.5%、13.8%,差异无统计学意义(P> 0.05)。结论:西洛他唑联合尼可地尔对LEAOD患者治疗效果显著,有效降低了baPWV值和CD36水平,提高了ABI,而且安全性较高,值得在临床广泛应用。

Objective:To investigate the effect of cilostazol combined with nicorandil on brachial-ankle pulse wave velocity(baPWV),ankle-brachial index(ABI)and scavenger receptor CD36 in patients with lower extremity arteriosclerotic occlusive disease(LEAOD).Methods:A total of 116 patients with LEAOD were entrolled in this study.According to the random number table,the patients were divided into control group and treatment group,58 cases in each group.The control group were treated with cilostazol and the treatment group were given cilostazol combined with nicorandil.The clinical effects,baPWV,ABI and the levels of CD36 before and after treatment were compared between the two groups.At the same time,the incidence of adverse reactions was compared between the two groups.Results:After the treatment,the effective rate was only 74.1%in the control group,but 91.4% in treatment group,the difference was statistically significant(P<0.05);There was no significant difference in baPWV,ABI and CD36 levels between the two groups before treatment.After treatment,baPWV and the levels of CD36 in both groups were significantly decreased,ABI was significantly increased,and baPWV and the levels of CD36 decreased more and ABI increased more in the treatment group(all P<0.05).The incidence of adverse reactions was 15.5%in the control group and 13.8%in treatment group respectively,there was no significant difference between the two groups(P>0.05).Conclusion:Cilostazol combined with nicorandil has a significant therapeutic effect on patients with LEAOD,it can effectively reduce the baPWV and CD36 level,increase the ABI and high safety,which is worth widely used in clinical practice.